Page 118 - Mployee Wellness Programs News Today

Two VCs from Merck Global Health Innovation Fund recently offered fundraising advice for digital health companies. They told these firms to expect slower funding timelines, urged them not to be afraid of down or flat rounds, and advised them to spend time nailing down the specifics of their growth narrative.

The healthcare industry will continue to shift more toward more home-based care offerings in the coming years, 7WireVentures said in a new report. The venture firm also gave some other predictions — including that established healthcare stakeholders will be forced to partner with non-traditional digital health companies and that the greater use of home-based solutions will lead to more personalized care plans.

Due to the end of the Medicaid continuous enrollment provision, at least 1.5 million Medicaid enrollees have lost coverage as of June 29, according to KFF. About 71% of those who were disenrolled from Medicaid were disenrolled for procedural reasons.

Corvitas brings Thermo Fisher Scientific registries that gather data about how approved therapies are working in the real world. The acquisition will complement PPD, the contract research organization that Thermo Fisher purchased in 2021.

Insurtechs like Bright Health Group, Clover Health and Oscar Health set out to disrupt health insurance — but have they actually done so? Not in a positive way, several experts say.

Johnson & Johnson’s oral psoriasis drug met the goals of a mid-stage clinical study, and the pharma giant now plans to advance the twice-daily pill to Phase 3 testing. J&J is one of several biopharmaceutical companies developing pill alternatives to biologic drugs that are injected or infused.

Butterfly Network recently launched an AI tool that can provide medical practitioners with an accurate B-line count from just a six-second lung ultrasound clip. By automatically counting B-lines in a lung image, the tool helps doctors quickly identify and assess a patient's lung issues at the point of care.

During a recent virtual panel discussion, health system executives discussed what it should ideally look like when health system leaders come together to launch a digital project. They stressed it is vital to assemble a diversified decision-making team and that leaders should prioritize addressing the organization’s challenges and opportunities rather than being captivated by flashy new products.

Dry eye disease drug Xiidra is the centerpiece of the Bausch + Lomb acquisition. The deal with Novartis also includes two experimental products, one for eye pain and the other a medical device for delivering medicines to the eye.

Experts suggest that the healthcare benefits landscape is evolving rapidly. Tell us whether you agree or disagree and what you think may be driving these changes. Your participation in this research will ensure the report results will be a valuable resource for you and the healthcare industry as a whole.